Background. The involvement of T-cell immunoglobulin mucin-3 (Tim-3) in the regulation of solid organ transplantation rejection is largely unknown. We used galectin-9 (Tim-3 ligand) to evaluate the effect and mechanisms of Tim-3/galectin-9 pathway in an allogeneic heart transplant model. Methods. The murine cardiac transplant model from BALB/c (H-2d) to C57BL/6 (H-2b) was built. The recipients were administered with galectin-9 for 7 days from day 1 or day 3 posttransplant. The complete cessation of cardiac contractility was defined as the observation endpoint. The effect of galectin-9 on cell proliferation was assessed by mixed lymphocyte reaction. Histology and immunohistochemistry were performed to estimate the severity of rejection. The phenotype and cytokine profile of lymphocytes were analyzed by flow cytometry. Results. In vitro, galectin-9 suppressed the proliferation of lymphocytes mixed lymphocyte reactions in a dose-and ␤-galactoside-dependent manner. In vivo, galectin-9 treatment from day 1 to day 3 posttransplant achieved similar survival time of grafts (median survival time, 22.7Ϯ1.2 vs. 23.0Ϯ1.0 days). The prolonged survival time was associated with reduced infiltration of CD4 and CD8 lymphocytes in allografts. Furthermore, the intragraft transcriptional profiling in galectin-9-treated group showed reduction of IFN-␥ and IL-17 mRNA but elevation of Ebi-3 and galectin-9 mRNA. Flow cytometry analysis indicated that galectin-9 treatment reduced the ratio of T helper (Th) 1 and Th17 cells in the draining lymph nodes and peripheral blood. Conclusions. A short-course administration of galectin-9 significantly prolonged the survival of fully allogeneic cardiac allografts, which was associated with the suppression of Th1 and Th17 immune responses.
T
-cell immunoglobulin mucin-3 (Tim-3) is a surface molecule preferentially expressed on T helper (Th) 1 and Th17 cells (1) . Important roles of Tim-3 in regulating Th1/ Th2 responses in autoimmune diseases have been illustrated (2, 3) . Tim-3 also plays an important role in solid organ transplantation whereas Tim-3 may provide a useful surrogate marker for prognosis of graft rejection. As a matter of fact, highly elevated Tim-3 mRNA levels in urinary cells were detected in clinical kidney transplant recipients suffering from acute rejection compared with the recipients with nonacute rejection or stable transplant (4) . Previous studies have identified galectin-9 as the ligand of Tim-3. Engaging Tim-3 with galectin-9 triggers a significant signal cascade to induce the death of Th1 cells (5) . More recently, researchers found that galectin-9 could inhibit the differentiation of Th17 cells in vitro. This effect was related to its engagement with Tim-3 on Th17 cells (6) . The cytotoxic effect of galectin-9 against activated Th1 cells and Th17 cells led us to speculate that this protein might serve as a novel immunosuppressant in organ transplantation. In our previous study, we demonstrated that galectin-9 could protect skin grafts in a stringent skin trans- plant model (7) , but there was no research to explore the role of galectin-9 and its therapeutic potential in vascularized organ transplantation.
The little information about the therapeutic effect of galectin-9 may be ascribed to its unstable structure. Galectin-9 belongs to the galectin family with specific affinity to a group of proteins modified with ␤-galactoside-containing glycan. It contains two tandem-repeat carbohydrate recognition domains connected by a linker peptide that is highly susceptible to proteolysis. In this study, we used the mutant human galectin-9, which lacks the entire linker peptide and is resistant to degradation (8) , to explore its therapeutic effect and mechanisms.
MATERIALS AND METHODS

Animals
BALB/c (H-2 d ) and C57BL/6 (H-2 b ) mice were maintained separately at the Animal Facility of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, under controlled conditions (specific pathogen free, 22°C
, 55% humidity, and 12h day/night). Male mice (8 -12 week old, weight 20 -25 g) were selected for the study. All experimental procedures on animals used in this study were performed under a protocol approved by the Institutional Animal Care and Use Committee at the Tongji Medical College.
Cardiac Transplantation
Mouse cervical cardiac transplantation was performed as described previously (9) . Briefly, the recipient mice were anesthetized by intraperitoneal pentobarbital. Cardiac grafts obtained from BALB/c (H-2 d ) mice or C57BL/6(H-2 b ) mice were transplanted to C57BL/6 (H-2 b ) mice. We observed the graft daily, and the complete cessation of cardiac contractility was defined as the endpoint. The day of operation (POD) was recorded as POD 0.
Preparation and Administration of Galectin-9
Human stable-form galectin-9 was prepared as described previously (8) . Briefly, galectin-9 was expressed using a pET expression system (Novagen, Madison, WI) in Escherichia coli BL21 (DE3) and purified with a lactose-agarose column (Seikagaku Kogyo, Tokyo, Japan), dialyzed against phosphate-buffered saline (PBS) and then endotoxin was eliminated with Cellufine ETclean-L (Chisso, Tokyo, Japan). The galectin-9 preparation used in this study is more than 95% pure as determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, with 0.12 ng endotoxin/mg protein on Limulus turbidimetric kinetic assays using a Toxnometer ET-2000 instrument (Wako, Osaka, Japan). Protein concentration was determined using a bicinchoninic acid assay reagent (Pierce, Rockford, IL) with bovine serum albumin as a standard. Galectin-9 was administered daily by intraperitoneal injection from POD 1 to POD 7. To test whether the antirejection response was potent enough to revert the ongoing rejection events; a group of mice was administered with galectin-9 from POD 3 to POD 9. As a control group, solvent (PBS) was administered instead.
T cell isolation and Dendritic Cell Propagation
Spleens were homogenized and passed through a 70-m cell strainer. Responder T cells from C57BL/6 mice were purified from spleen cells with a Pan T Cell Isolation Kit (Miltenyi Biotec, Bergisch Gladbach, Germany) (Ͼ95% purity by CD3 ϩ flow cytometry; eBioscience). BALB/c mice bone marrow-derived dendritic cells (BM-DCs) were prepared as described previously (10) . Briefly, bone marrow cells were flushed from the femurs and tibias of BALB/c mice, depleted of red blood cells, and cultured in six well plates (2ϫ10 6 mL Ϫ1 ) in complete Roswell Park Memorial Institute 1640 containing 10 ng/mL granulocyte macrophage-colony stimulating factor and 10 ng/mL IL-4 (Peprotech, London, UK). At 48 hr, nonadherent cells were removed. On day 6, nonadherent and loosely adherent cells were harvested.
Mixed Lymphocyte Culture Assays
C57BL/6 T cells (3ϫ10 5 per well) were incubated with MMC-treated (50 g/mL) BALB/c DCs (2ϫ10 4 per well) in the presence of galectin-9 (1, 5, 10, and 100 g/mL) or PBS control. Some groups were exposed to different concentrations of galectin-9 (1, 5, and 10 g/mL) in the presence of 10 mM lactose. After culture at 37°C for 4 days, the cells were pulsed with 1Ci of [ 
Fluorescence-Activated Cell Sorter
Phenotype analysis of lymphocytes was performed at different time points after galectin-9 treatment. The following monoclonal antibodies were used in these studies: anti-CD3 antigen-presenting cell, anti-CD4 PE-Cy7, anti-Tim-3 PE, anti-Tim-1 PE, and appropriate isotype control monoclonal antibodies (eBioscience, San Diego, CA). Cells were stained for 30 min at room temperature, washed (PBS with 1% bovine serum albumin), fixed in 1% formaldehyde. For intracellular staining, whole peripheral blood was diluted 1:1 volume with Roswell Park Memorial Institute 1640 medium. Then the culture system was supplemented with 200 ng/mL phorbol myristate acetate, 400 ng/mL ionomycin (SigmaAldrich), and monensin (for IL-17) or brefeldin A interferon-␥ (for IFN-␥), according to the instructions provided by eBioscience (San Diego, CA). After incubating for 4 hr, surface staining for CD4 (PE-Cy7) was performed. The red blood cells were then removed with Tris-NH 4 Cl buffer (pH 7.2). After washing, the cells were fixed and permeabilized with Fixation and Permeabilization Buffer (eBioscience) and stained with IL-17 Alexa Fluor 647 (eBioscience) or IFN-␥ antigen-presenting cell (Biolegend, CA, USA) at 4°C in the dark for 30 min. After washing, the cells suspended in fluorescence-activated cell sorter buffer were analyzed by flow cytometry (BD FACSAria, San Jose, CA) and FACS Aria software (BD Biosciences).
Quantitative Real-Time Polymerase Chain Reaction and ELISA
Cardiac graft tissues were harvested at POD 7 (for all goups) and POD 14 (for the treated group) after transplantation. The serum was collected at the same time. The levels of serum IFN-␥, IL-17, and IL-4 were measured by standard sandwich cytokine ELISA (R&D Systems, Minneapolis, MN) according to the manufacturer's directions (Bio-Tek Instruments, Inc.). RNA extracted from grafts with Trizol (Invitrogen) was reverse transcribed to cDNA with reverse transcription kits (Invitrogen). Quantitative real-time polymerase chain reaction (PCR) was performed on Rotor Gene 3000 (Corbett Research, Sydney, Australia) and a Quantitect SYBR Green PCR Kit (Toyobo, Osaka, Japan) according to the manufacturer's protocol. PCR amplification was performed for 45 cycles at 95°C for 15 sec, 56°C for 15 sec, and 72°C for 20 sec. Each PCR was performed in triplicate. Samples were electrophoresed on a 1.5% agarose gel to confirm that nonspecific amplification did not occur. Results were expressed with the comparative CT method relative to the housekeeping gene GAPDH. Oligonucleotides used as primers in this study are shown in Table 1 .
Histology and Immunohistochemistry
The grafts were harvested on POD 7, fixed in 10% phosphate-buffered formalin and embedded in paraffin. Sections were prepared and stained with hematoxylin-eosin stains. Parallel sections were analyzed for CD4 and CD8 (Santa Cruz Biotechnology, Santa Cruz, CA) by immunohistochemistry.
Data Analysis
Statistical analysis of survival curves was performed by the Kaplan-Meier log-rank test. Other comparisons were made using Student's t test. A value of P less than 0.05 was considered statistically significant.
RESULTS
Administration of Galectin-9 Prolonged the Survival of Allogeneic Cardiac Grafts in Mice
We have previously demonstrated that galectin-9 contributed to the prolongation of survival in fully allogeneic skin transplantation. To further explore the mechanisms, we used a heterotopic allogeneic cardiac transplantation model. Fully major histocompatibility complex mismatched grafts from BALB/c (H-2 d ) mice were transplanted into C57BL/6 (H-2 b ) recipients treated with galectin-9 during different time frames (POD 1-7 or POD 3-9). Control recipients were treated with PBS. No other immunosuppressants were used in this study. Galectin-9-treated allografts survived significantly longer (mean survival timeϭ22.7Ϯ1.2 days; 23.0Ϯ1.0 days, POD 1-7 and POD 3-9, respectively) than PBS-treated allografts (7.2Ϯ0.4 days; Fig. 1, PϽ0.001 ). In addition, the administration of galectin-9 starting at POD 3 enhanced survival time comparable with administration starting at POD 1 (23.0Ϯ1.0 days vs. 22.7Ϯ1.2 days, Pϭ0.63). These results indicated that galectin-9 could serve as an important therapeutic strategy in the early stage of allograft rejection.
Galectin-9 Reduces Lymphocyte Infiltration in Cardiac Allografts
Histologic characteristics of galectin-9-treated and PBS-treated grafts were compared with syngeneic grafts on Days Post Transplant Percent Graft Survival (%) FIGURE 1. Administration of galectin-9 prolongs survival of allogeneic grafts. Heterotopic heart grafts were transplanted from fully mismatched BALB/c mice into C57BL/6 recipients. Syngeneic transplantation was performed as a control. The recipients were treated with phospate-buffered saline (nϭ6) or human stable galectin-9 100 g/day starting at POD 1 (nϭ6) or POD 3 (nϭ6) for seven consecutive days. Rejection of cardiac grafts was defined as rejection by cessation of a palpable impulse. (Fig. 2A) . The PBS-treated group showed severe lymphocyte infiltration and myocardial necrosis, whereas the galectin-9-treated group showed less lymphocyte infiltration and almost normal tissue structure. Immunohistologic analysis indicated that galectin-9 treatment clearly reduced the infiltration of CD4 ϩ and CD8 ϩ T cells. The mean number of CD4 ϩ T cells per high-power field (PHF, original magnification: ϫ400) was 19.5Ϯ7.6 in the galectin-9-treated group compared with 55.8Ϯ4.3 in the PBS-treated group (PϽ0.0001, Fig. 2B) . Similarly, the infiltration of CD8 ϩ T cells was 22.8Ϯ3.4 PHF compared with 65.2Ϯ11.8 PHF (PϽ0.0001, Fig. 2C ).
Galectin-9 Inhibits Allogeneic T Cell Responses In vitro
Based on the earlier results, we further analyzed the direct immunosuppressive capacity of galectin-9 on alloimmune responses. We harvested purified T cells and BM-DCs derived from fully major histocompatibility complex mismatched mice. Incubation with 5 g/mL galectin-9 re-FIGURE 2. Administration of galectin-9 reduces intragraft cellular infiltration in vivo. Heart transplants were removed on POD7 from vehicle and galectin-9 100 g/day, POD 1-6 treated recipients. Syngeneic transplants were used as controls. (A) Hematoxylineosin staining was performed to evaluate cell infiltration and tissue integrity of the grafts (ϫ400). Immunohistochemical stainings for CD4 and CD8 were also performed (ϫ400). (B) The numbers of CD4 ϩ and CD8 ϩ T cells were counted in five different high power fields and quantified (original magnification:ϫ400). sulted in a statistically significant decrease in T lymphocyte proliferation compared with PBS buffer control (PϽ0.01).
The inhibitory effect was dose-dependent, as lower doses of galectin-9 (1 g/mL) resulted in no statistically significant suppression, whereas higher doses of galectin-9 led to more higher suppression by 75.4% (10 g/mL) and 81.3% (100 g/mL) compared with PBS control; P less than 0.01 (Fig. 3A) . To verify the specific role of beta-galactoside-binding activity in galectin-9-mediated suppression, we used lactose to block the glycan-binding site of galectin-9. Compared with the galectin-9-treated group (5 or 10 g/mL), the addition of lactose (10 mM) reversed the inhibitory effects of galectin-9 (Fig. 3B) . These results suggest that the galectin-9-mediated immune suppression is dependent on its lectin property.
Prolongation of Allograft Survival Mediated by Galectin-9 is Associated With Enhanced Immunosuppression in Graft Microenvironment
Based on the inhibitory effects of galectin-9 on alloimmune responses both in vitro and in vivo, we speculated that galectin-9 could promote an alleviated proinflammatory microenvironment. Peripheral blood serum and allografts were harvested at POD 7 and POD 14. As expected, profound reduction of IFN-␥ and IL-17 was found in galectin-9-treated recipients in the circulatory blood. Moreover, theses effects seemed to be extended to a longer observation time until POD 14 ( Fig. 4A and B) . However, the IL-4 level was at a similar level between the galectin-9-and PBS-treated groups at POD7 (Fig. 4C) . To investigate whether galectin-9 administration contributed to the immune suppression in the allograft microenvironment, we analyzed the expressions of immune-related genes in the grafts. After galectin-9 treatment, the levels of IFN-␥, Tim-3, and IL-17 mRNA decreased, but the levels of galectin-9 and Ebi-3 mRNA increased on POD7 (Fig. 4C) . There was no statistical difference in the levels of IL-4 and Foxp3 mRNA between groups 2 and 3 on POD7. These findings suggest that galectin-9 treatment not only suppresses the production of proinflammatory cytokines (IL-17 and IFN-␥) but also promotes the production of inhibitory mediators (galectin-9 and Ebi-3). 
Galectin-9 Treatment Reduces the Population of CD4
Cells, but Simultaneously Increases the CD4
؉ Tim-1 ؉ Cells As galectin-9 has been identified as the ligand of Tim-3, we hypothesized that its therapeutic effect could be associated with Tim-3 ϩ T cell apoptosis. On POD7, we harvested the regional draining lymph nodes around the heart grafts and analyzed the percentage of CD4 ϩ Tim-3 ϩ and CD4 ϩ Tim-1 ϩ cells. Compared with the PBS group, galectin-9 treatment resulted in significant depletion of CD4 ϩ Tim-3 ϩ cells (Fig.  5A ). Tim-1, which is preferentially expressed on Th2 cells, was analyzed for assessment of Th2-related immunity. Interestingly, we found an elevated percentage of CD4 ϩ Tim-1 ϩ cells in the draining lymph nodes (Fig. 5A ). These findings indicated that galectin-9 might prevent a Th1/Th2 imbalance. Based on the phenotype linkage between Tim-3 and Th1/Th17 cells, we sought to explore the percentage change of Th1 and Th17 cells among different groups. Consistent with the deletion of CD4 ϩ Tim-3 ϩ cells in the draining lymph nodes, the CD4 ϩ IL-17 ϩ and CD4 ϩ IFN-␥ ϩ cells were significantly lower in the galectin-9-treated recipients. Taken together, these data suggested that galectin-9 promoted the survival of allogeneic grafts by deletion of Th1/Th17 cells in vivo.
DISCUSSION
Here, we demonstrated that human stable form of galectin-9 leads to profound prolongation of survival of fully allogeneic heart transplants in mice. In previous studies, such as experimental autoimmune encephalomyelitis, collageninduced arthritis, Shwartzman reaction, and allergic asthma, a significant protective effect of galectin-9 was documented (5, (11) (12) (13) . Our research presents data about the protective roles of galectin-9 on solid organ transplantation for the first time.
Galectin-9 is the ligand for Tim-3, which is preferentially expressed on Th1 and Th17 cells (1, 5) . Th1 cells not only help to orchestrate the CD8 ϩ T cell cytotoxic responses but also participate in the attack of allografts. The mRNA of IFN-␥ which is the typical Th1 cytokine has been found to be elevated in the urinary cells from kidney transplant recipients undergoing acute rejection (4) . Although the Th1/Th2 paradigm has been extensively investigated in transplantation settings, the roles of Th1/Th2 cells in transplant rejection are still controversial (14, 15) . However, reduced Th1 responses are often beneficial in preventing transplant rejection (16 -18) . Tim-3, as the Th1 cell surface marker, provides an ideal target for deletion of unwanted immune responses. Using an antiTim-3 antibody to block the Tim-3/Tim-3 ligand pathway in an asthma model, Kearley et al. (19) found that the allergy response was obviously decreased by skewing the Th2 response toward a Th1-deviated type. However, currently there are no reports about the effect of deletional anti-Tim-3 antibody on immune responses. In this study, we find that galectin-9 treatment downregulates the Th1 response in allocardiac transplantation. Although this deletional effect cannot promote the permanent tolerance of the grafts, the prolongation of survival by galectin-9 in our model indicates that galectin-9 may serve as a powerful immunosuppressant in allograft rejection, especially in the control of activated Th1 responses.
In mice, Th17 cells are a newly identified T cell lineage that secret the pleiotropic cytokine IL-17 with multiple proinflammatory functions. Th17 cells have been shown to be important in the pathogenesis of autoimmune disease. The role of Th17 cells in transplantation rejection is controversial. However, to block the IL-17 and IL-17R interaction with IL-17R: Fc fusion protein can prolong the survival of allogeneic heart graft survival in rats (20) . More recently, it has been found that Th17 cells mediate an aggressive proinflammatory response in accelerated cardiac allograft rejection (14, 15, 21) . We found that galectin-9 led to a reduction of IL-17 in the 
Foxp3
ϩ T cells (Treg) share a common differentiation factor-transforming growth fact-␤. In the inflammatory milieu, especially in the presence of IL-6, naïve T cells are committed to a Th17 cells switch. The balance between Th17 and Treg might play a role in the control of transplant rejection (17) . We have detected Treg cells in the spleen and peripheral blood; however, we did not observe any differences between the treatment groups (data not shown). We speculate that other immunosuppressant agents may help to control the inflammation milieu and augment Treg switch. Indeed, further studies using galectin-9 in combination with other immunosuppressive drugs may cause this switch (under observations). In the previous studies, researchers found that administration of galectin-9 obviously reduced the symptoms of encephalomyelitis, which once was supposed to be a Th1-biased immune response (5). However, novel findings suggest that the autoimmune disease is largely ascribed to Th17 cells (22) . Thus, galectin-9 may be a key regulator in the control of Th1 and Th17 responses both in autoimmune and alloimmune diseases.
Recently, in addition to the deletional role of galectin-9 on Tim-3 ϩ T cells, galectin-9 has been also found to be implicated in the activation of innate immune cells, especially CD11b ϩ DCs (23). This finding is in agreement with previous results that galectin-9 can induce the maturation of human monocyte-derived DCs (24) . It is believable that galectin-9 promotes tissue inflammation through ligation with Tim-3 expressed on CD11b ϩ DCs. However, in in vitro models, we have found that the net effect of galectin-9 on T cell priming responses stimulated by mismatched DCs is suppressive. In vivo, our results are consistent with this finding that galectin-9 reduced the effector lymphocytes infiltrating in allograft regardless of the priming of the innate immune system. This prolongation effect is comparable between the delayed administration group and the immediate administration group. Galectin-9 gene was first discovered from tissues of Hodgkin's disease (25) , indicating that this molecule might have evolved due to a molecule implicated in the immune evasion in tumor immunology. New unraveled mechanisms regarding immune privilege suggest that galectin-9 is a widely existing protein involved in physiological and pathological conditions such as tumor cell growth (26, 27), thymocyte deletion (28) , and pregnancy (29) . We demonstrate herein that the use of a short course of galectin-9 promotes the survival of cardiac grafts, further supporting the immunomodulatory function of galectin-9. Interestingly, another two galectin family members, galectin-1 and galectin-10, were both found to be important mediators for Treg (30, 31) . There is no research to reveal that galectin-9 is involved in Treg function. Previously, Tim-3 ligand was detected on CD4 ϩ
CD25
ϩ Treg cells by Tim-3-Ig fusion protein staining (32) . However, the ligands for Tim-3 are galectin-9 and galectin-9-independent (33) .
An important factor affecting our results may be the stability of the recombinant galectin-9 protein. Galectin-9 is a tandem carbohydrate recognition domains-containing protein, which requires the bivalent galactoside-binding activity but not the linker peptide (8) . The modified protein that we used contains the truncated linker peptide which is resistant to proteolysis. In physiological conditions, galectin-9 is rapidly degraded after it exerts its functions. We speculate that the long linker peptide helps to stabilize galectin-9's activity. From the current data, the human-derived protein can function well in a mouse model, suggesting that galectin-9 is highly conserved.
In conclusion, galectin-9 is a highly conserved protein with powerful immunomodulatory functions in a mouse cardiac transplantation model. The modes of action include the reduction of Th1/Th17 cells, and the elevated immunosuppressive factors in the microenvironment of grafts.
